Collaboration with a leader in gene editing systems is Ionis’ latest move to expand and diversify its technology CRISPR-Cas gene editing is a natural extension of Ionis’ innovative approach to delivering potentially transformative therapies Ionis to hold webcast Nov. 14 at 8 a.m.
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
– Interim results show sustained reduction in hereditary angioedema attacks and no new safety signals in patients treated for one year CARLSBAD, Calif. , Nov. 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension
Ionis reports third quarter financial results
Advanced key priorities: initiated manufacturing infrastructure project to support growth Increased 2022 cash and investments guidance CARLSBAD, Calif. , Nov. 9, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the third quarter of
Ionis announces positive data from GSK’s Phase 2b clinical study of bepirovirsen
GSK plans to advance bepirovirsen into Phase 3 development program in 1H 2023 CARLSBAD, Calif. , Nov. 8, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBV
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology’s Kidney Week 2022
– IONIS-FB-L Rx achieved a 44% mean reduction in proteinuria in patients treated for 6 months – Roche to advance IONIS-FB-L Rx into Phase 3 development in H1 2023 CARLSBAD, Calif. , Nov. 7, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from